Uncategorized
FDA accepts Ocular Therapeutix NDA filing of Dextenza for postoperative ocular pain
Ocular Therapeutix has received FDA acceptance of its new drug application filing for Dextenza to treat postoperative ocular pain, according to a company release.“This is an important milestone for the company and we will continue to work diligently with the FDA as they complete their review,” Amar Sawhney, PhD, president, CEO and chairman of Ocular Therapeutix, said in the release.